3-58077255-G-T
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Moderate
The NM_001457.4(FLNB):c.502G>T(p.Gly168Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G168S) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001457.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FLNB | NM_001457.4 | c.502G>T | p.Gly168Cys | missense_variant | 2/46 | ENST00000295956.9 | NP_001448.2 | |
FLNB | NM_001164317.2 | c.502G>T | p.Gly168Cys | missense_variant | 2/47 | NP_001157789.1 | ||
FLNB | NM_001164318.2 | c.502G>T | p.Gly168Cys | missense_variant | 2/46 | NP_001157790.1 | ||
FLNB | NM_001164319.2 | c.502G>T | p.Gly168Cys | missense_variant | 2/45 | NP_001157791.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FLNB | ENST00000295956.9 | c.502G>T | p.Gly168Cys | missense_variant | 2/46 | 1 | NM_001457.4 | ENSP00000295956.5 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not specified Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 08, 2019 | The FLNB c.502G>T; p.Gly168Cys variant has been described in at least one individual with atelosteogenesis type III (Daniel 2012). It is absent from general population databases (Exome Variant Server and Genome Aggregation Database), indicating it is not a common polymorphism. The glycine at codon 168 is highly conserved in the CH2 domain, and computational algorithms (PolyPhen-2, SIFT) predict that this variant is deleterious. Additionally, other variants at this codon (c.502G>A; p.Gly168Ser and c.503G>T; p.Gly168Val) have been described in individuals affected with FLNB-related disorders, such as atelosteogenesis types I and III and Larsen syndrome (Bicknell 2007, Daniel 2012, Farrington-Rock 2006). Based on available information, the p.Gly168Cys variant is considered likely pathogenic. REFERNECES Bicknell L et al. A molecular and clinical study of Larsen syndrome caused by mutations in FLNB. J Med Genet. 2007 Feb;44(2):89-98. Daniel P et al. Disease-associated mutations in the actin-binding domain of filamin B cause cytoplasmic focal accumulations correlating with disease severity. Hum Mutat. 2012 Apr;33(4):665-73. Farrington-Rock C et al. Mutations in two regions of FLNB result in atelosteogenesis I and III. Hum Mutat. 2006 Jul;27(7):705-10. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at